StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report issued on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

BioLineRx Stock Up 1.7 %

Shares of BioLineRx stock opened at $0.47 on Tuesday. BioLineRx has a 52-week low of $0.43 and a 52-week high of $1.93. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The business’s 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.66. The firm has a market cap of $37.56 million, a PE ratio of -0.62 and a beta of 1.46.

BioLineRx (NASDAQ:BLRX) last announced its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. On average, analysts predict that BioLineRx will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp purchased a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned about 0.15% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.